Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence

Abstract Tyrosine kinases are important therapeutic targets in drug discovery high-throughput screening programs. Homogeneous time-resolved fluorescence (HTRF) eliminates many of the problems associated with some conventional screening assay methodologies and this has made the development of tyrosine kinase HTRF assays an exciting prospect for pharmaceutical companies. The authors illustrate the utility of this technology in the light of experience within five pharmaceutical companies.